These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26084553)

  • 41. Poly(styrene oxide)-poly(ethylene oxide) block copolymers: From "classical" chemotherapeutic nanocarriers to active cell-response inducers.
    Cambón A; Rey-Rico A; Barbosa S; Soltero JF; Yeates SG; Brea J; Loza MI; Alvarez-Lorenzo C; Concheiro A; Taboada P; Mosquera V
    J Control Release; 2013 Apr; 167(1):68-75. PubMed ID: 23352909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced UDP-glucose Levels Are Associated with P-glycoprotein Over-expression in L1210 Cells and Limit Glucosylceramide Synthase Activity.
    Turáková K; Pavlíková L; Messingerová L; Lakatoš B; Breier A; Sulová Z
    Anticancer Res; 2015 May; 35(5):2627-34. PubMed ID: 25964538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spray-dried doxorubicin-albumin microparticulate systems for treatment of multidrug resistant melanomas.
    Jones AK; Bejugam NK; Nettey H; Addo R; D'Souza MJ
    J Drug Target; 2011 Jul; 19(6):427-33. PubMed ID: 20678033
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
    Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
    J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Mechanism of synergistic anti-tumor effect of PH II -7 with doxorubicin on multi-drug resistant HL-60/ADR cells].
    Zhang YJ; Wang R; Shao XF; Fan DM; Xu YF; Zhou Y; Liu F; Su Y; Xiong DS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):599-602. PubMed ID: 19175986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.
    Hu FQ; Zhang YY; You J; Yuan H; Du YZ
    Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.
    De Vincenzo R; Scambia G; Benedetti Panici P; Fattorossi A; Bonanno G; Ferlini C; Isola G; Pernisco S; Mancuso S
    Int J Cancer; 1996 Nov; 68(3):340-8. PubMed ID: 8903476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Construction of glucosylceramide synthase-specific siRNA expression vector and its efficiency in reversal of drug resistance in breast carcinoma cells].
    Sun YL; Zhou GY; Li KN; Li WT; Song XR; Gao P
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):518-21. PubMed ID: 15949329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells.
    Ponnapakam AP; Liu J; Bhinge KN; Drew BA; Wang TL; Antoon JW; Nguyen TT; Dupart PS; Wang Y; Zhao M; Liu YY; Foroozesh M; Beckman BS
    Bioorg Med Chem; 2014 Feb; 22(4):1412-20. PubMed ID: 24457089
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
    Misra R; Das M; Sahoo BS; Sahoo SK
    Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Codelivery of Doxorubicin and Verapamil for Treating Multidrug Resistant Cancer Cells.
    Williams JB; Buchanan CM; Pitt WG
    Pharm Nanotechnol; 2018; 6(2):116-123. PubMed ID: 30207210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An interim analysis of phase I clinical trial of MCC-465, a doxorubicin (DXR) encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer.
    Matsumura Y
    Adv Exp Med Biol; 2003; 519():179-93. PubMed ID: 12675215
    [No Abstract]   [Full Text] [Related]  

  • 53. Controlled and Targeted Drug Delivery by a UV-responsive Liposome for Overcoming Chemo-resistance in Non-Hodgkin Lymphoma.
    Li H; Guo K; Wu C; Shu L; Guo S; Hou J; Zhao N; Wei L; Man X; Zhang L
    Chem Biol Drug Des; 2015 Oct; 86(4):783-94. PubMed ID: 25739815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.
    Patwardhan GA; Zhang QJ; Yin D; Gupta V; Bao J; Senkal CE; Ogretmen B; Cabot MC; Shah GV; Sylvester PW; Jazwinski SM; Liu YY
    PLoS One; 2009 Sep; 4(9):e6938. PubMed ID: 19742320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceramide Metabolism Regulated by Sphingomyelin Synthase 2 Is Associated with Acquisition of Chemoresistance via Exosomes in Human Leukemia Cells.
    Taniguchi M; Nagaya S; Yuyama K; Kotani A; Igarashi Y; Okazaki T
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142562
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A role for ceramide in driving cancer cell resistance to doxorubicin.
    Liu YY; Yu JY; Yin D; Patwardhan GA; Gupta V; Hirabayashi Y; Holleran WM; Giuliano AE; Jazwinski SM; Gouaze-Andersson V; Consoli DP; Cabot MC
    FASEB J; 2008 Jul; 22(7):2541-51. PubMed ID: 18245173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interactions of adriamycin, cytochrome c, and serum albumin with lipid monolayers containing poly(ethylene glycol)-ceramide.
    Zhao H; Dubielecka PM; Söderlund T; Kinnunen PK
    Biophys J; 2002 Aug; 83(2):954-67. PubMed ID: 12124277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells.
    Liu YY; Han TY; Yu JY; Bitterman A; Le A; Giuliano AE; Cabot MC
    J Lipid Res; 2004 May; 45(5):933-40. PubMed ID: 14967819
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES).
    Siddiqui A; Gupta V; Liu YY; Nazzal S
    Int J Pharm; 2012 Jul; 431(1-2):222-9. PubMed ID: 22562053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic PEG-ceramide nanomicelles synergize with salinomycin to target both liver cancer cells and cancer stem cells.
    Wang M; Xie F; Wen X; Chen H; Zhang H; Liu J; Zhang H; Zou H; Yu Y; Chen Y; Sun Z; Wang X; Zhang G; Yin C; Sun D; Gao J; Jiang B; Zhong Y; Lu Y
    Nanomedicine (Lond); 2017 May; 12(9):1025-1042. PubMed ID: 28440698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.